Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$154.5 million.

  • Beam Therapeutics' Net Cash Flow rose 77.24% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.9 million, marking a year-over-year decrease of 35.85%. This contributed to the annual value of -$154.5 million for FY2024, which is 177.60% down from last year.
  • Per Beam Therapeutics' latest filing, its Net Cash Flow stood at -$154.5 million for FY2024, which was down 177.60% from $199.1 million recorded in FY2023.
  • Beam Therapeutics' 5-year Net Cash Flow high stood at $395.7 million for FY2021, and its period low was -$327.2 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$154.5 million (2024), whereas its average is -$94.2 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 229.86% in 2020, then slumped by 182.69% in 2022.
  • Over the past 5 years, Beam Therapeutics' Net Cash Flow (Yearly) stood at $126.5 million in 2020, then soared by 212.93% to $395.7 million in 2021, then tumbled by 182.69% to -$327.2 million in 2022, then soared by 160.84% to $199.1 million in 2023, then plummeted by 177.60% to -$154.5 million in 2024.